Phase 2 N=31 Treatment of Acute Migraine Headache in Children
Migrainous Headache
Primary: The Number of Subjects With a Numeric Rating Scale Score (NRS) of Zero at Two Hours. — 5; 12 participants — p=0.03
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=473 Treatment of Multiple Attacks of Acute Migraine (0462-025)
Migraine Headache
Primary: Pain Relief at 2 Hours During the First Migraine Attack Period — 246; 30; 74; 52 participants
Phase 4 N=220 Corticosteroids for Acute Migraine in the Emergency Department
Migraine
Primary: Headache Days as Self-reported by Participants — 3.0; 3.3 days
Phase 4 N=50 Trial of Comprehensive Migraine Intervention
Migraine
Primary: Migraine Functional Impairment as Measured by Score on the Headache Impact Test 6 (HIT6) Scale — 59; 56 units on a scale
Phase 4 N=208 Diphenhydramine for Acute Migraine
Migraine
Primary: Number of Participants With Sustained Headache Relief Assessed by Self-evaluation — 40; 38 Participants
Phase 3 N=2,231 Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
Acute Migraine
Primary: Percentage of Participants Who Are Headache Pain Free — 28.2; 32.2; 15.3 percentage of participants — p=<0.001
Phase 3 N=1,466 Trial in Adult Subjects With Acute Migraines
Migraine, With or Without Aura
Primary: Percentage of Participants With Freedom From Pain at 2 Hours Post-dose — 21.2; 10.9 percentage of participants — p=< 0.0001
Phase 3 N=902 Phase 3 Study of MAP0004 in Adult Migraineurs
Migraine Disorders
Primary: Number of Subjects With Pain Relief at 2 Hours From Time of First Dose — 136; 231 participants
Phase 3 N=207 Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)
Migraine
Primary: Number of Participants Who Are Pain Free at 2 Hours Post-Dose — 61; 27 Participants
Phase 2 N=676 MK3207 for Treatment of Acute Migraines (3207-005)
Migraine
Primary: Pain Freedom (PF) — 13; 4; 5; 16 Participants — p=<0.001
Phase 2 N=44 Normobaric Oxygen (NBO) Therapy in Acute Migraine
Migraine
Primary: Change in Pain Scores From 0-30 Minutes on a Visual Analog Scale (VAS) — 1.38; 1.22 units on a scale — p=0.674
Phase 3 N=1,162 Safety and Efficacy Study in Adult Subjects With Acute Migraines
Migraine, With or Without Aura
Primary: Percentage of Participants With Freedom From Pain at 2 Hours Post-dose — 19.2; 14.2 percentage of participants — p=0.0298
Phase 3 N=1,594 Maximizing Outcomes in Treating Acute Migraine
Migraine
Primary: Percentage of Subjects Reporting Headache Pain Freedom — 85; 14 Participants — p=<0.001
Phase 3 N=205 Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Migraine
Primary: Persistent Headache Pain Free at 24 Hours — 26; 19 Participants
Phase 4 N=512 Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
Migraine
Primary: Change From Baseline in Mean Monthly Hours of at Least Moderate Headache Pain Intensity Over Months 1, 2, and 3 — -23.38; -31.33 hours/month — p=< 0.001
Phase 3 N=1,186 Safety and Efficacy in Adult Subjects With Acute Migraines
Migraine, With or Without Aura
Primary: Percentage of Participants With Freedom From Pain at 2 Hours Post-dose — 19.6; 12.0 Percentage of participants — p=0.0006
Phase 3 N=1,380 Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
Migraine
Primary: Number of Participants With Pain Freedom (PF) at 2 Hours Post-Dose — 56; 89; 101; 29 Participants — p=<0.001
N/A N=568 Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
Migraine · Episodic Migraine · Headache
Primary: Change in MMD (Monthly Migraine Days) — -3.04; -2.14 migraine days per month
Phase 3 N=28 Greater Occipital Nerve Block With Bupivacaine for Acute Migraine
Migraine
Primary: Number of Participants Who Achieve Freedom From Headache — 4; 0 Participants
Phase 4 N=232 Drug and Non-Drug Treatment Of Severe Migraine
Migraine Headache
Primary: Change in Number of Migraine Episodes Per 30 Days at Month 10. — -2.1; -2.1; -2.2; -3.3 Number of Migraine episodes — p=< .01
Phase 4 N=160 Acetaminophen and Ibuprofen With and Without Magnesium and Primary Migraine in Childhood
Migraine
Primary: Pain-relief — 5.6; 5.1; 2.25; 2.2 units on a scale*hr
N/A N=26 An Exploratory Prospective Trial of Rescue Acupuncture for the Treatment of Acute Migraine
Migraine
Primary: Change of Migraine Headache Pain — 16; 2 Participants
Phase 4 N=40 Ticagrelor Therapy for RefrACTORy Migraine Study
Migraine · Headache · Migraine Headache
Primary: Total Number of Responders — 17 Participants
Phase 3 N=349 Metoclopramide for Migraine: A Dose Finding Study
Migraine
Primary: Pain Intensity Score — 4.7; 4.9; 5.3 scores on a scale
Phase 3 N=1,703 Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)
Migraine
Primary: Number of Patients Reporting Pain Freedom at 2 Hours Postdose — 29; 88; 88; 39 Participants — p=<0.001
Phase 2 N=84 CHOCOlate MeLatonin for AdolescenT MigrainE
Migraine
Primary: Change in Mean Visual Analog Scale (VAS) Score — -2.3; -2.7 cm
Phase 3 N=167 DFN-02 Open Label Safety Study in Patients With Acute Migraine
Acute Migraine
Primary: Number of Participants With Treatment Emergent Adverse Events — 120 Participants
Phase 3 N=1,473 MK0462 in Treatment of Migraine With Recurrence (MK0462-022)
Migraine Headache
Primary: Pain Relief at 2 Hours After the Initial Dose of Test Drug — 285; 322; 106; 172 Participants
Phase 4 N=209 Dexamethasone for Migraine - Dose Comparison
Migraine
Primary: Number of Subjects With Headaches Who Have Sustained Headache Relief for 48 Hours — 35; 42 Participants
Phase 3 N=1,633 A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
Migraine
Primary: Percentage of Participants That Are Pain Free 2 Hours Postdose During the First Attack — 25.8; 29.3; 8.4 percentage of participants — p=<0.001